This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
For informational purposes only — not medical advice
Get a free vaccination guide and nearby clinic recommendations — straight to your inbox.
How serious?
Risk of death
No
Vaccine available?
Time to symptoms
Countries affected
Active outbreaks
Risk for travelers is low unless exposed to blood products or unsterile medical equipment. Avoid tattoos, piercings, and medical procedures in facilities with questionable hygiene. No pre-travel vaccination exists — prevention relies on avoiding blood exposure. Unlike hepatitis A and B, there is no vaccine for hepatitis C.
Bloodborne viral infection causing chronic liver disease, cirrhosis, and liver cancer. Curable with direct-acting antivirals (>95% cure rate) but no vaccine exists. ~50 million people chronically infected worldwide.
Viral infection causing liver inflammation, primarily spread through blood contact.
Hepatitis C is caused by the Hepatitis C virus (HCV), an enveloped RNA virus of the family Flaviviridae with 8 major genotypes (GT1–8) and numerous subtypes. Unlike hepatitis A and B, there is NO vaccine for hepatitis C. Transmission is bloodborne: unsafe injections and blood transfusions (major route globally), injection drug use, needlestick injuries, tattooing/piercing with unsterilized equipment, and less commonly sexual or vertical (mother-to-child) transmission. HCV is remarkable for its ability to evade the immune system — 55–85% of acutely infected individuals develop chronic infection (vs. <5% for hepatitis B in adults). The revolution in treatment came with direct-acting antivirals (DAAs) achieving >95% sustained virologic response (cure), transforming hepatitis C from a chronic death sentence to a curable disease.
Seek medical care if:
Jaundice (yellow skin/eyes) with dark urine — may indicate acute hepatitis
Known HCV positive with: abdominal swelling (ascites), confusion (encephalopathy), or vomiting blood (variceal bleeding)
Unexplained chronic fatigue with elevated liver enzymes
Seek EMERGENCY care if:
Vomiting large amounts of blood or passing black tarry stools (variceal hemorrhage — life-threatening)
Confusion, drowsiness, or personality changes in known liver disease (hepatic encephalopathy)
Severe right upper abdominal pain with fever (possible liver abscess or acute decompensation)
Fever and abdominal distension in patient with ascites (spontaneous bacterial peritonitis)
Most common signs and symptoms
Acute hepatitis C (first 6 months after infection):
80% of acute infections are ASYMPTOMATIC — the "silent epidemic"
When symptomatic (20%): fatigue, anorexia, nausea, abdominal discomfort, dark urine, jaundice (usually mild)
Incubation: 2–26 weeks (average 6–10 weeks)
Fulminant hepatitis: extremely rare (<1%)
Spontaneous clearance: 15–45% clear the virus without treatment (more likely in women, those with symptomatic acute infection, and IL28B CC genotype)
Chronic hepatitis C (>6 months — affects 55–85% of infected):
Decades of silent progression: Most patients are asymptomatic for 10–30 years while liver damage accumulates
Non-specific symptoms: Chronic fatigue (most common complaint), "brain fog," depression, myalgia, arthralgia
Extrahepatic manifestations (up to 40% of chronic HCV patients): – Mixed cryoglobulinemia: vasculitis, purpura, arthritis, glomerulonephritis – Type 2 diabetes mellitus (2–3× increased risk) – Porphyria cutanea tarda (blistering skin disease) – B-cell non-Hodgkin lymphoma – Lichen planus, sicca syndrome, thyroid disease
Advanced liver disease (after 15–30 years): – Cirrhosis develops in 15–30% of chronically infected – Portal hypertension: ascites, esophageal varices, hepatic encephalopathy – Hepatocellular carcinoma (HCC): 1–4% per year in cirrhotics
Knowing the symptoms is the first step to a quick response.
Typical disease course:
Extrahepatic manifestations: Cryoglobulinemia (10–15%), glomerulonephritis, porphyria cutanea tarda, lymphoma, diabetes.
How this disease is identified
Screening (who to test):
All adults ≥18 years at least once (CDC universal screening recommendation, 2020)
PWID, recipients of blood products before 1992, HIV+, hemodialysis, healthcare exposure, children of HCV+ mothers, elevated ALT
Diagnostic algorithm:
Step 1 — Anti-HCV antibody (EIA/ELISA): Screening test; positive indicates current or past infection; seroconversion 4–10 weeks after exposure
Step 2 — HCV RNA (quantitative PCR): Confirms active infection (detectable from 1–2 weeks after exposure); also used to monitor treatment response – Anti-HCV positive + HCV RNA positive = active infection (acute or chronic) – Anti-HCV positive + HCV RNA negative = resolved infection (spontaneous or treated)
Step 3 — HCV genotyping: Determines genotype (1–8); pangenotypic DAAs (sofosbuvir/velpatasvir) have reduced the importance of genotyping but still relevant for some regimens
Fibrosis assessment: FIB-4 index, APRI score (non-invasive); transient elastography (FibroScan) — cutoff >12.5 kPa suggests cirrhosis; liver biopsy rarely needed now
Liver function: ALT may be normal even with significant fibrosis (poor correlation)
HCC screening: Ultrasound + AFP every 6 months in patients with cirrhosis (continues even after cure)
Available treatment methods
Direct-acting antivirals (DAAs) — curative treatment: DAAs target HCV proteins (NS3/4A protease, NS5A, NS5B polymerase) and cure >95% of patients with 8–12 weeks of oral therapy.
Pangenotypic regimens (all genotypes — WHO preferred):
Sofosbuvir/Velpatasvir (Epclusa): 1 tablet daily × 12 weeks; >95% SVR12; WHO-recommended first-line for all patients
Glecaprevir/Pibrentasvir (Mavyret): 3 tablets daily × 8 weeks (non-cirrhotic, treatment-naive) or 12 weeks (cirrhotic); >97% SVR12
Genotype-specific (if pangenotypic unavailable):
GT1/4: Ledipasvir/Sofosbuvir (Harvoni) × 8–12 weeks
GT1/2/4–6: Elbasvir/Grazoprevir (Zepatier) × 12 weeks
Special populations:
Decompensated cirrhosis: Sofosbuvir/Velpatasvir (avoid protease inhibitors)
Post-transplant: DAAs are safe and effective
HIV/HCV co-infection: Standard DAA regimens; check drug interactions with antiretrovirals
Renal impairment (eGFR <30): Glecaprevir/Pibrentasvir preferred (no sofosbuvir dose adjustment needed since 2024 data)
Monitoring:
SVR12 (sustained virologic response at 12 weeks post-treatment) = cure
Liver cancer surveillance continues indefinitely in patients with pre-treatment cirrhosis (cure does not eliminate HCC risk)
No post-cure immunity — reinfection is possible
Most cases are effectively treated with early diagnosis.
How to protect yourself
No vaccine exists for hepatitis C. Prevention relies on risk reduction:
Blood safety:
Universal screening of donated blood and organs (eliminated transfusion-associated HCV in high-income countries)
Safe injection practices: single-use needles and syringes
WHO "injection safety" campaigns in low/middle-income countries
Harm reduction (for PWID):
Needle/syringe exchange programs
Opioid substitution therapy (methadone, buprenorphine)
Supervised injection facilities
"Treatment as prevention": curing active infections reduces community viral load
Healthcare settings:
Standard precautions for blood/body fluid exposure
Proper sterilization of medical and dental equipment
Post-exposure protocol: baseline HCV RNA → repeat at 4–6 weeks → early treatment if seroconversion
For travelers:
Avoid unsterile medical/dental procedures in countries with limited infection control
Decline unnecessary injections (some settings routinely give injectable medications when oral would suffice)
If tattooing/piercing desired: ensure single-use needles and ink pots
Carry personal medical kit (sterile needles, sutures) for emergency medical care in remote areas
Avoid sharing personal items that may have blood on them (razors, toothbrushes, nail clippers)
Preparation is the best protection.
Risk to travelers:
Hepatitis C is NOT a typical travel vaccine concern (no vaccine exists), but travelers should be aware of bloodborne exposure risks
Higher risk scenarios: – Medical/dental tourism in countries with suboptimal infection control (especially injectable procedures, dialysis, transfusions) – Tattoos and piercings abroad (especially in unregulated settings) – Prolonged stays in high-prevalence countries with potential for emergency medical care – Adventure travelers who may need emergency wound treatment in remote areas
Protective measures: – Carry a personal medical kit with sterile supplies (needles, sutures, wound care) for remote travel – Medical evacuation insurance for serious injuries (to avoid emergency transfusions in unscreened settings) – Decline unnecessary injections — ask if oral alternatives exist – If receiving medical care abroad, confirm use of single-use needles/syringes
Post-travel: Consider HCV screening if had invasive medical/dental procedures, tattoos, or blood exposure during travel
Hepatitis C is now curable — early detection and treatment prevent all complications
Statistics and geographic data
WHO estimates 50 million people living with chronic HCV infection (2024), with 1 million new infections and ~242,000 deaths annually:
Highest prevalence regions: – Eastern Mediterranean/Middle East: Egypt (historical iatrogenic transmission — anti-schistosomal injection campaigns; now leading global elimination effort), Pakistan (~8 million infected) – Central Asia: Mongolia, Uzbekistan, Georgia – Sub-Saharan Africa: Cameroon, Gabon, Burundi – East Asia: China (~10 million), Japan (declining)
Genotype distribution: GT1 (global, most common), GT3 (South Asia, highest cirrhosis/HCC risk), GT4 (Middle East, Africa), GT6 (Southeast Asia)
Transmission drivers by region: – High-income: injection drug use (primary); MSM with HIV co-infection – Low/middle-income: unsafe medical injections (WHO estimates 5% of injections in some countries use reused equipment), unscreened blood products
Elimination progress: WHO target: 90% diagnosed, 80% treated by 2030. As of 2024, only ~36% diagnosed and ~20% treated globally. Egypt is closest to elimination (treated >4 million people with DAAs through national program).
Cost: DAA treatment costs have dropped dramatically — generic sofosbuvir/velpatasvir available for <$100/course in some LMIC (vs. $84,000 original Sovaldi price in 2013)
Who is most at risk
Injection drug use (current or past), receipt of blood products before screening era, unsafe medical or dental procedures, needle-stick injuries in healthcare settings, tattooing or piercing with non-sterile equipment, travel to countries with high HCV prevalence and potential exposure to unscreened blood products.
Potential complications
Natural history without treatment (over 20–30 years):
Chronic hepatitis: 55–85% of infected individuals
Cirrhosis: 15–30% of chronically infected (accelerated by alcohol, HIV co-infection, NAFLD, male sex, age at infection >40)
Hepatocellular carcinoma (HCC): 1–4% per year in cirrhotics (HCV is the leading cause of liver transplantation globally)
Liver-related death: significant contributor to the ~242,000 hepatitis C deaths annually (WHO 2024)
Specific complications:
Portal hypertension: Esophageal/gastric varices (variceal bleeding mortality 15–20%), ascites, spontaneous bacterial peritonitis, hepatic encephalopathy
Hepatocellular carcinoma: Even after DAA cure, patients with pre-existing cirrhosis retain 1–3% annual HCC risk — lifelong surveillance required
Cryoglobulinemic vasculitis: Immune complex deposition → purpura, neuropathy, glomerulonephritis; resolves in most after HCV cure
Renal disease: Membranoproliferative glomerulonephritis (MPGN) — most common HCV renal complication
Metabolic complications: Insulin resistance, type 2 diabetes, steatosis (especially GT3)
B-cell lymphoma: 20–30× increased risk of splenic marginal zone lymphoma; decreases after cure
Cardiovascular risk: Emerging evidence of increased atherosclerosis and cardiovascular mortality
After cure (SVR12):
Most extrahepatic manifestations resolve
Fibrosis regression occurs over years (even cirrhosis can partially reverse)
HCC surveillance must continue in those with pre-treatment advanced fibrosis/cirrhosis
Expected outcomes and recovery
With treatment: Direct-acting antivirals (DAAs) cure >95% of chronic HCV infections in 8–12 weeks, regardless of genotype.
Without treatment: 55–85% of acute infections become chronic. Of those:
15–30% develop cirrhosis within 20 years.
1–4% per year of cirrhotics develop hepatocellular carcinoma (HCC).
HCV is a leading cause of liver transplantation worldwide.
Prognostic factors: Alcohol use, HIV co-infection, hepatitis B co-infection, and metabolic syndrome accelerate liver fibrosis. Early treatment before cirrhosis yields near-normal life expectancy.
Spontaneous clearance: 15–45% of acute infections resolve without treatment, especially in young women and those with symptomatic acute hepatitis.
The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.
Full terms of useRecent epidemiological data from the World Health Organization Global Health Observatory.
Source: WHO GHO OData ↗
Source: WHO GHO OData ↗
This data is provided for informational purposes. Please consult official WHO sources for the most current information.
View WHO data source →Know which vaccine you need? Great. Not sure? Just tell us your destination — we will figure it out and match you with a clinic. Free, no obligation.